September 15, 2020 01:48 PM EDTUpdated September 16, 04:46 AM
FDA+
Coronavirus

NIH ‘very con­cerned’ about se­ri­ous side ef­fect in As­traZeneca's PhI­II Covid-19 tri­al

Kaiser Health News

The FDA is weigh­ing whether to fol­low British reg­u­la­tors in re­sum­ing a coro­n­avirus vac­cine tri­al that was halt­ed when a par­tic­i­pant suf­fered spinal cord …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times